In short
This article discusses a clinical trial investigating the use of EDV2209, a MEK1/2 inhibitor, in patients with subarachnoid hemorrhage (SAH). The study aims to evaluate the safety, tolerability, and potential clinical benefits of EDV2209 in treating this severe condition. The trial is designed as a randomized, double-blind, placebo-controlled study with multiple ascending doses, marking the first time this drug is being tested in humans for this specific condition.
At a glance
- Study Type
- Interventional, randomized, double-blind, placebo-controlled, multiple-ascending-dose, first-in-human trial
- Drug Name
- EDV2209 (1,4-Diamino-2,3-Dicyano-1,4-Bis(O-Aminophenylmercapto)Butadiene Hemiethanolate)
- Condition
- Subarachnoid Hemorrhage (SAH)
- Primary Objective
- Assess safety and tolerability of EDV2209 in SAH patients
- Key Inclusion Criteria
- Age 18-80, moderate to severe SAH, symptoms <8 hours, WFNS score 1-5
- Key Exclusion Criteria
- SAH due to trauma, expected survival <48 hours, severe concomitant conditions
- Primary Endpoints
- Frequency of adverse events, changes in vital signs and lab results
- Secondary Endpoints
- Clinical outcomes (NIHSS, mRS, GOS-E), length of hospital stay, pharmacokinetics
- Follow-up Duration
- Up to 84 days after SAH
What is EDV2209?
EDV2209 is a new medication being studied for the treatment of subarachnoid hemorrhage (SAH), a type of bleeding in the brain. Its scientific name is 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene hemiethanolate. This medication is classified as a MEK1/2 inhibitor, which means it works by blocking specific proteins involved in cell growth and survival.
What is Subarachnoid Hemorrhage (SAH)?
Subarachnoid hemorrhage (SAH) is a serious medical condition where bleeding occurs in the space between the brain and the thin tissues that cover it. This is often caused by a ruptured aneurysm, which is a weak spot in a blood vessel that bulges and then bursts. SAH is a life-threatening emergency that requires immediate medical attention.
How EDV2209 Works
EDV2209 is designed to help patients with SAH by targeting specific cellular processes. As a MEK1/2 inhibitor, it may help reduce the damage caused by the bleeding and potentially improve outcomes for patients. However, the exact mechanisms are still being studied in clinical trials.
Clinical Trial Details
A clinical trial is currently underway to evaluate EDV2209. Here are some key details about the study:
- It is a randomized, double-blind, placebo-controlled trial. This means that participants are randomly assigned to receive either EDV2209 or a placebo, and neither the patients nor the researchers know who is receiving which treatment.
- The trial is testing multiple ascending doses of EDV2209, which means they are gradually increasing the dose to determine the safest and most effective amount.
- This is a first-in-human trial, meaning it's the first time EDV2209 is being tested in people.
- The main goal is to determine the safety and tolerability of EDV2209 in patients with SAH.
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria. Some of the key eligibility requirements include:
- Age 18-80 years
- Diagnosed with moderate or severe SAH caused by a ruptured aneurysm
- Symptoms started less than 8 hours before treatment
- A specific severity score (WFNS score) between 1-5
There are also several factors that would exclude a patient from participating, such as other causes of bleeding, expected survival less than 48 hours, or pregnancy.
Potential Benefits
While the effectiveness of EDV2209 is still being studied, the researchers hope to see several potential benefits:
- Improved clinical outcomes for SAH patients
- Reduced length of stay in intensive care and hospital
- Better overall recovery as measured by various neurological scales
Safety and Side Effects
A primary focus of the clinical trial is to assess the safety of EDV2209. Researchers will be closely monitoring:
- The frequency and severity of side effects
- Changes in vital signs and laboratory results
- Any serious adverse events that may occur
It's important to note that as this is a new medication, not all potential side effects may be known at this time.
How EDV2209 is Administered
EDV2209 is given as a solution for injection. In this clinical trial, it is administered intracerebroventricularly, which means it is injected directly into the fluid-filled spaces (ventricles) of the brain. This method of administration allows the medication to reach the affected areas more directly.
It's important to remember that EDV2209 is still an experimental treatment. If you or a loved one has experienced a subarachnoid hemorrhage, always consult with your healthcare provider about the most appropriate treatment options available.